Landos Biopharma, Inc. (NASDAQ:LABP) gapped down prior to trading on Thursday . The stock had previously closed at $14.83, but opened at $14.40. Landos Biopharma shares last traded at $14.40, with a volume of 8 shares.
LABP has been the topic of several analyst reports. SVB Leerink reaffirmed a “buy” rating on shares of Landos Biopharma in a research note on Thursday, October 7th. Jonestrading initiated coverage on shares of Landos Biopharma in a research note on Thursday, September 23rd. They issued a “buy” rating and a $39.00 target price on the stock. Raymond James lifted their target price on shares of Landos Biopharma from $33.00 to $35.00 and gave the stock an “outperform” rating in a research note on Friday, July 30th. Finally, Zacks Investment Research upgraded shares of Landos Biopharma from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Wednesday, July 28th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $25.83.
The firm’s fifty day moving average is $14.30 and its two-hundred day moving average is $12.17.
Several hedge funds have recently made changes to their positions in LABP. American International Group Inc. bought a new stake in shares of Landos Biopharma during the 1st quarter valued at $35,000. New York State Common Retirement Fund bought a new stake in shares of Landos Biopharma during the 1st quarter valued at $70,000. Morgan Stanley boosted its holdings in shares of Landos Biopharma by 1,337.0% during the 2nd quarter. Morgan Stanley now owns 6,912 shares of the company’s stock valued at $81,000 after buying an additional 6,431 shares in the last quarter. California State Teachers Retirement System bought a new stake in shares of Landos Biopharma during the 1st quarter valued at $92,000. Finally, Teacher Retirement System of Texas bought a new stake in shares of Landos Biopharma during the 1st quarter valued at $96,000. Hedge funds and other institutional investors own 56.63% of the company’s stock.
About Landos Biopharma (NASDAQ:LABP)
Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases.
Receive News & Ratings for Landos Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Landos Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.